IGM Biosciences, Inc. (IGMS) NASDAQ

1.16

+0.03(+2.65%)

Updated at May 09 10:55AM

Currency In USD

IGM Biosciences, Inc.

Address

325 East Middlefield Road

Mountain View, CA 94043

United States of America

Phone

650 965 7873

Sector

Healthcare

Industry

Biotechnology

Employees

149

First IPO Date

September 18, 2019

Key Executives

NameTitlePayYear Born
Ms. Mary Beth Harler M.D.Chief Executive Officer & Director754,5391965
Dr. Lisa L. Decker Ph.D.Chief Business Officer555,0881969
Dr. Angus M. Sinclair Ph.D.Executive Vice President of Research0N/A
Mr. TS HarigopalSenior Vice President of Group Operations0N/A
Mr. Paul C. Graffagnino J.D.Senior Vice President of Legal Affairs0N/A
Ms. Suzette TauberChief Human Resources Officer01964
Dr. Eric W. Humke M.D., Ph.D.Senior Vice President & Head of Clinical Research and Development0N/A
Mr. Steven WeberSenior Vice President, Corporate Controller & Principal Accounting Officer01977
Dr. Marvin S. Peterson Ph.D.Executive Vice President of Process Development & Manufacturing0N/A
Ms. Elaine SapinosoSenior Vice President of Quality0N/A

Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.